scholarly journals The Navjeevan Advanced Medical Science (NAMS): A Novel Noninvasive, Nonpharmaceutical Breakthrough Ecosystemic Innovation in Treatment of Cancer

2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 195s-195s
Author(s):  
M.G. Desai
Keyword(s):  
Cell Damage ◽  
Medical Science ◽  
Stage Iv ◽  
Clinical Results ◽  
The Body ◽  
Body Type ◽  
Patient Centered ◽  
Food Ingredients ◽  
Intrinsic Factors ◽  
Stage Iv Cancer

Background: Advances made in recent years by cancer research have led to a wide variety of new therapeutic options. While many of these new modalities require pharmaceutical, invasive or radiotherapeutic intervention, the parameters defining benefit can be defined narrowly (as in x months to relapse). The NAMS (Navjeevan Advanced Medical Science) developed over 15 years by a team of practicing researchers, offers a fresh noninvasive, ecohealth/ecosystemic approach, utilizing an individualized patient centered approach called “precision.” Aim: NAMS has developed a totally new scientific approach with a unique conceptualization that totally breaks with conventional methods. Over the past decade, NAMS has successfully treated with its chemical-free medicine more than 300 patients with various cancers, most of whom were deemed “impossible cases” or stage IV cancer, with positive results beyond 80%. Methods: This report also presents case studies to provide both a quantitative and qualitative analysis of the clinical results including some of the more extreme patient monographs in the treatment of cancer where the current scientific therapies offered no hope of healing. NAMS is at the heart of an innovative serendipity heterodox in the effective treatment of cancer because it comes from a precise medicine with strong ecosystemic and ecological health (ecohealth) approach. NAMS borrows the ways of a treatment ecosystemic. Indeed, as part of a more systemic approach to cancer that favors the identification of internal and external causal factors with respect to the environment and its elimination by the administration of more targeted “qualifying” molecules, based on specific plant and fruit extracts, to effectively treat cancer cells. Results: Why the results are remarkable at NAMS? First, the particular diet resets disturbed health, fighting and preventive powers of the body; second reason, NAMS treats body as a whole and does not divide body in departments and treats at cell damage and disease causing factors level. NAMS treats disease in general as imbalances of the body. NAMS treatment produces fastest results by noninvasive way, avoiding use of any chemical or synthetic medicines. Balancing of the disturbed vital body molecules which are oxidants, free radicals and toxins is the cornerstone of NAMS research. Disturbance in vital molecules and accumulation of toxins lead to cell damage where ever they are in excess. In this process, NAMS uses phytoceutical actives, food actives, food ingredients balancing, body´s intrinsic factors (body´s own acid, enzymes, hormone) balancing and corrections. Body typing, correlating the body type with all the extrinsic actives used in treatment and taking support of the body intrinsic actives in enhancing the effect in general… producing the button on effect on many of the instances. Conclusion: In summary, NAMS does not treat patients, disease wise, it treats patients body wise. Diseases develop in body because of disruption of health balancing molecules.

scholarly journals Two Cases of Small Cell Cancer of the Maxillary Sinus Treated with Cisplatin plus Irinotecan and Radiotherapy

2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
Kiyoaki Tsukahara ◽  
Kazuhiro Nakamura ◽  
Ray Motohashi ◽  
Hiroki Sato
Keyword(s):  
Adverse Events ◽  
Oral Mucositis ◽  
Blood Cells ◽  
Cell Cancer ◽  
White Blood Cells ◽  
Stage Iv ◽  
Small Cell ◽  
The Body ◽  
Small Cell Cancer ◽  
Stage Iv Cancer

Background. Small cell carcinoma (SmCC) in the nasal cavity and paranasal sinuses is very rare, and definitive therapies have not yet been established.Methods. Chemoradiotherapy comprised 60 Gy of external radiation, with the administration of irinotecan intravenously at 60 mg/m2on days 1, 8, and 15 and cisplatin at 60 mg/m2on day 1.Results. Case 1 involved a 66-year-old woman with stage III cancer. Adverse events included decreased white blood cells, anemia, and oral mucositis, all Grade 2. The patient remained free of cancer as of 3 years and 6 months after completing the treatment. Case 2 involved a 60-year-old man with stage IV cancer. He also experienced adverse events of decreased white blood cells, anemia, and oral mucositis, all Grade 2. He died after 11 months due to metastases throughout the body.Conclusions. The results suggest that this regimen may be tolerable as a therapy for this type of carcinoma.

scholarly journals Maladaptive Immunity and Metastasizing Cancer

2020 ◽  
Vol 3 (1) ◽  
pp. 31-34
Author(s):  
J Dochniak Michael ◽  
Keyword(s):  
Immune System ◽  
Cancer Survival ◽  
Immunoglobulin E ◽  
Survival Rates ◽  
Stage Iv ◽  
The Body ◽  
Humoral Immune ◽  
Metastatic Cells ◽  
Endogenous Proteins ◽  
Stage Iv Cancer

The ability of innate immunity to inhibit metastatic cells is limited, based on Stage IV cancer survival rates. The dysregulation of the immune system through acquired immunity may result in pathological conditions that alter metastatic cells. Immunoglobulin-E (IgE) antibodies developed by the humoral immune system are a significant contributor to maladaptive immunity. Hypersensitivities are maladaptive immune reactions against harmless allergens. Forced allergen-specific immune responses may provide immediate-type allergies that affect the incidence and prevalence of endogenous proteins essential for metastasizing cells. Furthermore, allergies may shift the body’s resource allocation away from metastasizing cells to IgE-primed effector-cell proliferation. Therefore, research efforts need to explore if hyper-allergenic skin creams can be used to starve-out metastatic cells, wherever they are in the body, to determine if maladaptive immunotherapy is a viable treatment for Stage IV cancer.

Comparative assessment of the clinical efficacy of various amlodipine isomers in 1st and 2nd degree arterial hypertension patients

2021 ◽  
Vol 20 (2) ◽  
pp. 439-448
Author(s):  
Dmitriy Ermakov ◽  
Olga Pashanova
Keyword(s):  
Arterial Hypertension ◽  
Diastolic Pressure ◽  
Medical Science ◽  
Systolic Pressure ◽  
Clinical Results ◽  
Comparative Assessment ◽  
The Body ◽  
Pressure Reduction ◽  
Hypertensive Disease ◽  
Medication Dosage

Objective: The paper presents the results of clinical trials of medications based on S-amlodipine and S/R-amlodipine. Materials and methods: A total of 140 patients diagnosed with arterial hypertension of I and II degree were included into study, in particular, 70 patients with 1st degree and another 70 patients with 2nd degree hypertensive disease. A group consisted of 80 male (57%) and 60 female patients (43%) aged from 45 to 73 years. The average age of the examined patients was 62.1±5.8 years. Duration of the disease was established between 1 and 22 years (12.5±1.2 years on average). Results and discussion: The stereoselectivity mechanisms of the studied amlodipine enantiomers were found to initiate the activity of only one S-amlodipine isomer. Applying S-amlodipine in treatment was proved to improve significantly the clinical results, facilitate the course of hypertensive disease, and normalize the structure and functional heart condition. After 8 weeks of amlodipine-based treatment, the diastolic pressure in groups receiving S-amlodipine reduced by 20-25% and systolic pressure reduction was between 20% and 31%. Among patients taking the original amlodipine medication consisting of S and R enantiomers, the diastolic pressure decrease was between 19.4% and 24%, and the systolic pressure reduced from 16.7% to 27.37%. Conclusions: By using S-amlodipine, the prescribed medication dosage can be reduced by 50%, which allows diminishing the drug load on the body and lessen the side effects. Bangladesh Journal of Medical Science Vol.20(2) 2021 p.439-448

Men’s Hunger, Food Consumption, and Preferences for Female Body Types

2014 ◽  
Vol 45 (6) ◽  
pp. 495-497 ◽  
Author(s):  
Nicolas Guéguen
Keyword(s):  
Food Consumption ◽  
Female Body ◽  
The Body ◽  
Slender Body ◽  
Mediation Effect ◽  
Point Scale ◽  
Body Type ◽  
Experimental Conditions

Nelson and Morrison (2005 , study 3) reported that men who feel hungry preferred heavier women. The present study replicates these results by using real photographs of women and examines the mediation effect of hunger scores. Men were solicited while entering or leaving a restaurant and asked to report their hunger on a 10-point scale. Afterwards, they were presented with three photographs of a woman in a bikini: One with a slim body type, one with a slender body type, and one with a slightly chubby body. The participants were asked to indicate their preference. Results showed that the participants entering the restaurant preferred the chubby body type more while satiated men preferred the thinner or slender body types. It was also found that the relation between experimental conditions and the choices of the body type was mediated by men’s hunger scores.

Mechanisms of Nickel-Induced Cell Damage in Allergic Contact Dermatitis and Nutritional Intervention Strategies

2020 ◽  
Vol 20 (7) ◽  
pp. 1010-1014 ◽  
Author(s):  
Dana Filatova ◽  
Christine Cherpak
Keyword(s):  
Lipid Peroxidation ◽  
Contact Dermatitis ◽  
Oxidative Damage ◽  
Allergic Contact Dermatitis ◽  
Cell Damage ◽  
Consumer Products ◽  
The Body ◽  
Cellular Damage ◽  
Nutritional Interventions ◽  
Allergic Contact

Background: Hypersensitivity to nickel is a very common cause of allergic contact dermatitis since this metal is largely present in industrial and consumer products as well as in some commonly consumed foods, air, soil, and water. In nickel-sensitized individuals, a cell-mediated delayed hypersensitivity response results in contact to dermatitis due to mucous membranes coming in long-term contact with nickel-containing objects. This process involves the generation of reactive oxidative species and lipid peroxidation-induced oxidative damage. Immunologically, the involvement of T helper (h)-1 and Th-2 cells, as well as the reduced function of T regulatory cells, are of importance. The toxicity, mutagenicity, and carcinogenicity of nickel are attributed to the generation of reactive oxygen species and induction of oxidative damage via lipid peroxidation, which results in DNA damage. Objective: The aim of this research is to identify nutritionally actionable interventions that can intercept nickel-induced cell damage due to their antioxidant capacities. Conclusion: Nutritional interventions may be used to modulate immune dysregulation, thereby intercepting nickel-induced cellular damage. Among these nutritional interventions are a low-nickel diet and an antioxidant-rich diet that is sufficient in iron needed to minimize nickel absorption. These dietary approaches not only reduce the likelihood of nickel toxicity by minimizing nickel exposure but also help prevent oxidative damage by supplying the body with antioxidants that neutralize free radicals.

scholarly journals Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush

2019 ◽  
Vol 12 (1) ◽  
pp. 84-90 ◽  
Author(s):  
Nobuhiko Seki ◽  
Ryosuke Ochiai ◽  
Terunobu Haruyama ◽  
Masashi Ishihara ◽  
Maika Natsume ◽  
...  
Keyword(s):  
Substance P ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Stage Iv ◽  
Subsequent Treatment ◽  
Treatment Schedule ◽  
Weekly Schedule ◽  
Patient Centered ◽  
Neurokinin 1 ◽  
Dermatological Side Effects

Common dermatological side-effects associated with erlotinib, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), include pruritus and skin rash, which are mediated by substance P, leading to the occasional discontinuation of cancer treatment. Aprepitant is an antagonist of neurokinin-1 receptor, through which substance P activates the pruritogens. Thus, aprepitant is expected to offer a promising option for the treatment of erlotinib-induced pruritus. However, the appropriate treatment schedule for aprepitant administration is under consideration. Here, we discuss the need for flexible adjustment of the treatment schedule for aprepitant administration against erlotinib-induced refractory pruritus and skin rush. A 71-year-old female smoker presented with stage IV EGFR-mutated lung adenocarcinoma. She was started on erlotinib at 150 mg/day. However, by 28 days, severe pruritus and acneiform skin rush resistant to standard therapies occurred, resulting in the interruption of erlotinib therapy. After recovery, she was restarted on erlotinib at 100 mg/day. However, severe pruritus and skin rush developed again within 2 weeks. Then, we started the first 3-day dose of aprepitant (125 mg on day 1, 80 mg on day 3, and 80 mg on day 5) based on the results of the previous prospective study, which showed the success rate of 100% with at least the second dose of aprepitant. However, the pruritus and skin rush exacerbated again within 4 weeks. Therefore, we started the second 3-day dose of aprepitant, but in vain. At this point, as the patient-centered medicine, bi-weekly schedule of the 3-day dose of aprepitant was considered and, then, adopted. As the results, the pruritus and skin rush remained well-controlled throughout the subsequent treatment with erlotinib.

Exploratory Study of Advance Care Discussions Among Chinese American and White Stage IV Cancer Patients at an American Tertiary Medical Center

2021 ◽  
pp. 104990912110126
Author(s):  
Avery Caz Glover ◽  
Courtney Schroeder ◽  
Emma Ernst ◽  
Tamara Vesel
Keyword(s):  
Cancer Patients ◽  
Exploratory Study ◽  
Stage Iv ◽  
Chinese American ◽  
Chinese Americans ◽  
Do Not Resuscitate ◽  
Essential Components ◽  
Advance Care ◽  
Stage Iv Cancer ◽  
White Patients

Purpose: Timely advance care discussions are essential components of quality care for diverse populations; however, little is known about these conversations among Chinese American cancer patients. This exploratory study describes differences in advance care discussions and planning between Chinese American and White advanced cancer patients. Methods: We collected data for 63 Chinese American and 63 White stage IV cancer patients who died between 2013 and 2018. We compared: frequency and timing of prognosis, goals of care (GOC), and end-of-life care (EOLC) discussions in the final year of life; family inclusion in discussions; healthcare proxy (HCP) identification; do not resuscitate (DNR) order, do not intubate (DNI) order, and other advance directive (AD) completion. We did not conduct statistical tests due to the study’s exploratory nature. Results: Among Chinese American and White patients, respectively, 76% and 71% had prognosis, 51% and 56% had GOC, and 89% and 84% had EOLC discussions. Prognosis, GOC, and EOLC discussions were held a median of 34.0, 15.5, and 34.0 days before death among Chinese American and 17.0, 13.0, and 24.0 days before death among White patients. Documentation rates among Chinese American and White patients were 79% and 76% for DNRs, 81% and 71% for DNIs, 79% and 81% for HCPs, and 52% and 40% for other ADs. Conclusions: Findings suggest that Chinese Americans had similar rates of advance care discussions, completed conversations earlier, and had similar to higher rates of AD documentation compared to White patients. Further studies are needed to confirm our preliminary findings.

scholarly journals Incidence of Severe Pain in Newly Diagnosed Ambulatory Patients with Stage IV Cancer

2012 ◽  
Vol 17 (5) ◽  
pp. 347-352 ◽  
Author(s):  
Thomas Isaac ◽  
Sherri O Stuver ◽  
Roger B Davis ◽  
Susan Block ◽  
Jane C Weeks ◽  
...  
Keyword(s):  
Head And Neck ◽  
Severe Pain ◽  
Stage Iv ◽  
Initial Visit ◽  
Newly Diagnosed ◽  
Ambulatory Oncology ◽  
Ambulatory Patients ◽  
Stage Iv Cancer ◽  
One Year ◽  
Thoracic Malignancies

BACKGROUND: Pain is common among cancer patients.OBJECTIVE: To characterize the incidence of severe pain among newly diagnosed patients with stage IV cancer in ambulatory care.METHODS: A retrospective cohort of 505 ambulatory oncology patients with newly diagnosed stage IV solid tumours at a comprehensive cancer centre (Dana-Farber Cancer Institute, Boston, Massachusetts, USA) was followed from January 1, 2004, to December 31, 2006. Pain intensity scores were extracted from electronic medical records. The incidence of severe pain was calculated using the maximum monthly pain scores reported at outpatient visits.RESULTS: Of the 505 patients included in the present study, 340 (67.3%) were pain-free at the initial visit, 90 (17.8%) experienced mild pain, 48 (9.5%) experienced moderate pain and 27 (5.4%) experienced severe pain. At least one episode of severe pain within one year of diagnosis was reported by 29.1% of patients. Patients with head and neck, gastrointestinal and thoracic malignancies were more likely to experience severe pain compared with patients with other types of cancer (52.6%, 33.9% and 30.5%, respectively). In the multivariable model, patients whose primary language was not English (OR 2.90 [95% CI 1.08 to 7.80]), patients who reported severe pain at the initial visit (OR 9.30 [95% CI 3.72 to 23.23]) and patients with head and neck (OR 10.17 [95% CI 2.87 to 36.00]) or gastrointestinal (OR 4.05 [95% CI 1.23 to 13.35]) cancers were more likely to report severe pain in the following year.CONCLUSIONS: The incidence of severe pain was high in ambulatory patients with newly diagnosed stage IV cancer.

Change in skeletal muscle index and its prognostic significance in conversion therapy for initially unresectable colorectal cancer.

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. 56-56
Author(s):  
Hiroaki Nozawa ◽  
Shigenobu Emoto ◽  
Koji Murono ◽  
Yasutaka Shuno ◽  
Soichiro Ishihara
Keyword(s):  
Colorectal Cancer ◽  
Skeletal Muscle ◽  
Muscle Mass ◽  
Skeletal Muscles ◽  
Systemic Chemotherapy ◽  
Stage Iv ◽  
The Body ◽  
Pharmacological Intervention ◽  
Conversion Therapy ◽  
Skeletal Muscle Index

56 Background: Systemic chemotherapy can cause loss of skeletal muscle mass in colorectal cancer (CRC) patients in the neoadjuvant and palliative settings. However, it is largely unknown how the body composition is changed by chemotherapy rendering unresectable CRC to resectable disease or how it affects the prognosis. This study aimed at elucidating the effects of systemic chemotherapy on skeletal muscles and survival in stage IV CRC patients who underwent conversion therapy. Methods: We reviewed 98 stage IV CRC patients who received systemic chemotherapy in our hospital. According to the treatment setting, patients were divided into the ‘Conversion’, ‘Neoadjuvant chemotherapy (NAC)’, and ‘Palliation’ groups. The cross-sectional area of skeletal muscles at the third lumbar level and changes in the skeletal muscle index (SMI), defined as the area divided by height squared, during chemotherapy were compared among patient groups. The effects of these parameters on prognosis were analyzed in the Conversion group. Results: The mean SMI increased by 8.0% during chemotherapy in the Conversion group (n = 38), whereas it decreased by 6.2% in the NAC group (n = 18) and 3.7% in the Palliation group (n = 42, p < 0.0001). Moreover, patients with increased SMI during chemotherapy had a better overall survival (OS) than those whose SMI decreased in the Conversion group (p = 0.021). The increase in SMI was an independent predictor of favorable OS on multivariate analysis (hazard ratio: 0.26). Conclusions: Stage IV CRC patients who underwent conversion to resection often had an increased SMI. As such an increase in SMI further conveys a survival benefit in conversion therapy, it may be important to make efforts to preserve muscle mass by meticulous approaches, such as nutritional support, muscle exercise programs, and pharmacological intervention even during chemotherapy in patients with metastatic CRC.

Late Stage Decomposition of Embalmed Cadavers

2021 ◽  
Vol 2 (1) ◽  
Author(s):  
Pilar Mata Tutor ◽  
Catherine Villoria Rojas ◽  
María Benito Sánchez
Keyword(s):  
Soft Tissue ◽  
Late Stage ◽  
Good Condition ◽  
Experimental Studies ◽  
The Body ◽  
Health Law ◽  
External Appearance ◽  
Intrinsic Factors ◽  
Preservation Technique ◽  
Extrinsic And Intrinsic Factors

Decomposition is a natural process that begins approximately four minutes after death and continues until the body is degraded to simpler biochemical components which are gradually recycled back to the environment. This process is dependent on extrinsic and intrinsic factors. Embalming is a chemical preservation technique that aims to preserve the external appearance of the body in good condition for an indeterminate period. In Spain, there is a lack of experimental studies carried out to analyse the variables that affect decomposition in embalmed bodies, therefore, in accordance with the conclusions reached by previous authors, it is hypothesised that embalmed bodies show quantifiable characteristics during the late stage decomposition which distinguish them from control, unembalmed, cadavers. An anthropological and statistical analysis was performed on 14 individuals from Cementerio Sur de Madrid exhumed after ten years according to the Mortuary Health Law of the Autonomous Region of Madrid. The preliminary results obtained showed that there is a qualitative and statistically significant relationship between the variables evaluated, being the presence or absence of soft tissue the most notable difference. The mortuary or thanatopraxy treatments performed before the burial and the microenvironmental conditions of the burial positively influence the soft tissue preservation on embalmed bodies. These results contribute to the understanding about the decomposition rate of an embalmed cadavers in cemeteries, and the related extrinsic variables.

Sign in / Sign up

Export Citation Format

Share Document